1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow PARP Inhibitor: new trials by email Literature Review of PARP Inhibitor trials Research Report on PARP Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors SRP1020 - Advanced Solid Tumors, PARP Inhibitor | Phase 1 / Phase 2 | Recruiting | Shanghai SciBrunch Therapeutics Co., Ltd. | 210 | 2026-01-08 | 2026-10-30 |
| Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy) - Malignant Gliomas, Radiotherapy | Phase 1 / Phase 2 | Active not recruiting | Centre Francois Baclesse | 91 | 2017-09-04 | 2025-12-04 |
Glioma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1)
Radiotherapy, Intensity-Modulated (1) · Temozolomide (1) · olaparib (1)
Centre Francois Baclesse (1) · Shanghai SciBrunch Therapeutics Co., Ltd. (1)
China (1) · France (1)